Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanyl Spray for Exercise-Induced Dyspnea in Cancer
NCT02597478Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fentanyl (transdermal patch + oral transmucosal lozenge) in Dyspnea (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Modified Dyspnea Borg Scale (Dyspnea Intensity). Started Jan 2016; status: completed.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
Dyspnea
Beyond the preview
Go deeper on NCT02597478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597478.